Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, pertussis, hepatitis B, haemophilus influenzae type b, and poliomyelitis vaccine
- Development stage
- Approved
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A hexavalent combination vaccine designed to provide active immunization against six major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib). This product typically combines the antigens found in a standard pentavalent vaccine (DTP-HepB-Hib) with the inactivated poliovirus vaccine (IPV) derived from the Salk strains (Mahoney, MEF-1, and Saukett). By consolidating these six components into a single injection, the vaccine simplifies pediatric immunization schedules, reduces the number of required needle sticks, and improves overall vaccination coverage. Various formulations exist using either whole-cell pertussis (DTwP) or acellular pertussis (DTaP) components, with major commercial examples including Sanofi's Hexaxim and GSK's Infanrix Hexa.
- Brand names
- HexaximHexyonHexacimaInfanrix HexaVaxelisEasySixShan6Shan-6Shan 6
- Other names
- hexavalent vaccineDTP-HepB-Hib-IPV vaccinepentavalent vaccine + Salk IPV
02
Targets
FHA (Filamentous hemagglutinin)Fimbrial antigen type 3HBsAg (Hepatitis B surface antigen)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria, tetanus, pertussis, hepatitis B, haemophilus influenzae type b, and poliomyelitis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, pertussis, hepatitis B, haemophilus influenzae type b, and poliomyelitis vaccine.